Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.anaptysbio.com
AnaptysBio Inc. News Releases
Get the latest updates from AnaptysBio Inc. News Releases directly as they happen.
Follow now 51 followers
Latest posts
Last updated 11 days ago
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
11 days ago
Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive...
Anaptys Announces Stock Repurchase Plan
about 2 months ago
SAN DIEGO , March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq...
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
3 months ago
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase...
Anaptys Announces Participation in March Investor Conferences
3 months ago
SAN DIEGO , Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq...
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
3 months ago
Achieved statistical significance on primary endpoint at Week 12 on mean change...
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
3 months ago
SAN DIEGO , Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq...
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
3 months ago
SAN DIEGO , Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq...
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
3 months ago
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular...
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
4 months ago
SAN DIEGO , Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq...
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
5 months ago
ANB032 was well tolerated across all doses with no safety signals observed...
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
6 months ago
Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic...
Anaptys Announces Participation in November and December Investor Conferences
6 months ago
SAN DIEGO , Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq...